Produits Chimiques Auxiliaires et de Synthèse SA

Produits Chimiques Auxiliaires et de Synthèse SA

Produits Chimiques Auxiliaires et de Synthèse SA

Overview
Date Founded

1962

Headquarters

23, rue Bossuet,Z. I. de la Vigne aux Loups,Longjumeau, Ile-de-France 91160

Type of Company

Public

Employees (Worldwide)

982

Industries

Chemicals

Company Description

Produits Chimiques Auxiliaires et de Synthèse SA specializes in developing, manufacturing, and selling of chemicals. It operates through the Pharmaceutical Synthesis and Fine Chemical sectors. The Pharmaceutical Synthesis sector manufactures active ingredients, generics, and biomaterials. The Fine Chemical sector comprises of polymers and insulators. The company was founded in 1962 and is headquartered in Longjumeau, France.

Website
In The News
Subscribe now to see full news coverage
Executives & Employees

Chief Executive Officer

Vice Chief Executive Officer

Chief Operating Officer

Deputy Chief Executive Officer-Finance & Administration

Scientific Director

Director-Research & Development

Financial Communication

Subscribe now to see full list of current and former executives
Board of Directors

Vice Chief Executive Officer at Produits Chimiques Auxiliaires et de Synthèse SA

Chief Technology Officer at Karhoo Ltd.

Former Chief Executive Officer at Cryo Diffusion SA

Chairman-Scientific Council at Institut Français des Sciences et Technologies des Transports

Former Chief Executive Officer at Quantel SA

Fund Advisor at Comgest SA

President, Chief Executive Officer & General Manager at Novacap SASU

Member, Board of Directors at Produits Chimiques Auxiliaires et de Synthèse SA

General Counsel at Novacap SASU

Strategy, M&A at Novacap SASU

Subscribe now to see full list of current and former board members
Paths to Produits Chimiques Auxiliaires et de Synthèse SA
Potential Connections via
Relationship Science
You
Produits Chimiques Auxiliaires et de Synthèse SA
Owners & Shareholders
Details Hidden

Portzamparc Gestion manages mutual funds as well as discretionary portfolios. Their investment process is primarily based on fundamental research, both in-house and shared within the parent group, which is complemented with the quantitative expertise of B*Capital. Their investment approach consists in security picking across asset classes, within the constraints of their clients' risk tolerance profile. They provide to their clients access to third-party products through an open architecture.In terms of equity Portzamparc Gestion invests both directly and through equity funds. Their direct investments favor French and European mid-caps. They have specific expertise in regional small and mid caps.

Details Hidden

Portzamparc Gestion manages mutual funds as well as discretionary portfolios. Their investment process is primarily based on fundamental research, both in-house and shared within the parent group, which is complemented with the quantitative expertise of B*Capital. Their investment approach consists in security picking across asset classes, within the constraints of their clients' risk tolerance profile. They provide to their clients access to third-party products through an open architecture.In terms of equity Portzamparc Gestion invests both directly and through equity funds. Their direct investments favor French and European mid-caps. They have specific expertise in regional small and mid caps.

Subscribe now to see full details
Recent Transactions
Details Hidden

Eurazeo SA (Private Equity), Novacap SASU purchase Produits Chimiques Auxiliaires et de Synthèse SA

Details Hidden

Eurazeo SA (Private Equity), Novacap SASU purchase Produits Chimiques Auxiliaires et de Synthèse SA

Details Hidden

MML Capital Partners LLP, Nactis SAS purchase Produits Chimiques Auxiliaires et de Synthèse SA /AromaticBus from Produits Chimiques Auxiliaires et de Synthèse SA

Subscribe now to see full list of recent transations
Transaction Advisors
Legal Advisor

Advised onEurazeo SA (Private Equity), Novacap SASU purchase Produits Chimiques Auxiliaires et de Synthèse SA

Investment Advisor

Advised onEurazeo SA (Private Equity), Novacap SASU purchase Produits Chimiques Auxiliaires et de Synthèse SA

Subscribe now to see transaction advisors for over 2.5 million organizations
Subscribe now to see transaction advisors for over 2.5 million organizations
Clients

Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Merck KGaA engages in the manufacturing of pharmaceutical and chemical products. It operates through the following segments: Healthcare, Life Science, and Performance Materials. The Healthcare segment comprises the businesses with prescription and over-the-counter pharmaceuticals and biopharmaceuticals as well as allergy products. The Life Science segment offers solutions to research and analytical laboratories in the pharmaceutical/biotechnology industry or in academic institutions, and customers manufacturing large- and small-molecule drugs. The Performance Materials segment includes specialty chemicals, which are used in a variety of end products. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Bukwang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include gastrointestinal, central nervous system and metabolic drugs. It also sells household supplies and gift sets. Bukwang Pharmaceutical was founded on October 17, 1960 and is headquartered in Seoul, South Korea.

Subscribe now to see 2 more clients
Subscribe now to see clients for over 2.5 million organizations
Key Stats and Financials As of 2016
Market Capitalization
$268M
Total Enterprise Value
$249M
Earnings Per Share
$0.49
Revenue
$192M
Net Profit
$6.83M
EBITDA
$20M
EBITDAMargin
10.4%
Total Debt
$64.7M
Total Equity
$97M
Enterprise Value Sales
1.3x
Enterprise Value EBITDAOperating
12.48x
TEVNet Income
36.45x
Debt TEV
0.26x
Three Year Compounded Annual Growth Rate Of Revenue
5.2%
Five Year Compounded Annual Growth Rate Of Revenue
3.13%
Subscribe now to see full financial details
Investments
Details Hidden

Pivert SAS develops plant based chemistry from a renewable and raw material. It develops processes and proprietary products in accordance with the biorefinery concept. The company was founded in May 29th, 2012 and is headquartered in Venette, France.

Subscribe now to see full investment details